Atossa Therapeutics Q1 net loss widens on higher legal and R&D expenses

Atossa Therapeutics

08/05/2026 13:53

Overview

U.S. biopharma firm's Q1 net loss widened yr/yr on higher R&D and legal expenses

Company secured FDA Orphan Drug and Rare Pediatric Disease designations for (Z)-endoxifen in new indications

Atossa added two medical directors to strengthen clinical leadership in breast oncology and rare diseases

Outlook

Company did not provide specific financial guidance for the current qtr or full yr

Result Drivers

R&D SPENDING - Higher clinical and pre-clinical trial costs for (Z)-endoxifen drove increased R&D expenses

LEGAL EXPENSES - Higher legal fees from patent litigation and IP management raised G&A costs

INTEREST INCOME DECLINE - Lower average cash balances led to reduced interest income

Company press release: ID:nPn2xR33Da

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$1.11
Q1 Net Income
-$9.59 mln
Q1 Operating Expenses
$9.87 mln
Q1 Operating Income
-$9.87 mln
Q1 Pretax Profit
-$9.59 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Atossa Therapeutics Inc is $24.00, about 323.3% above its May 7 closing price of $5.67

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)